In this week’s episode, John Stanford reports from Boston - the beating heart of global biotech - with insights from investors, scientists, and executives shaping the future of life sciences. He breaks down what the government shutdown means for FDA operations, unpacks the White House–Pfizer deal, and shares key takeaways from conversations on U.S. competitiveness, biotech investment, and the next generation of talent and technology.How do you see policy uncertainty affecting biotech innovation?Are U.S. policies doing enough to keep the next generation of scientists here?What biotech breakthroughs excite you most right now?If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps:0:00 Disclaimer: Not medical or investment advice0:23 Welcome from Boston - biotech capital of the world1:11 Government shutdown and FDA operations2:06 What’s paused at the FDA and why it matters2:29 Understanding the White House–Pfizer deal3:19 MFN pricing, TrumpRx, and tariff waivers4:07 Pfizer’s $70B U.S. investment and industry implications4:29 Key takeaways from Boston investor meetings4:58 Policy uncertainty and its impact on biotech investment5:29 Interest rate cuts and biotech’s comeback potential6:07 The growing threat to U.S. scientific talent6:33 The “brain drain” and its implications for America’s biotech future7:22 Boston’s role in championing life sciences7:50 Exciting new biotech modalities: gene therapy, RNA, and cell engineering9:34 Policy clarity, workforce development, and scientific momentum10:20 Closing thoughts: innovation across America10:40 Outro and call to action DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

Ver todos los episodios